Expertise in
5
conditions

Dr. Sharon A. Riddler

University Of Pittsburgh Physicians
Pittsburgh, PA
Expertise in
5
conditions
Specialties:Infectious Disease
Expertise in
5
conditions
OverviewInsuranceLocationsClinical Research

Overview

Sharon Riddler is an Infectious Disease provider in Pittsburgh, Pennsylvania. Dr. Riddler is highly rated in 5 conditions, according to our data. Her top areas of expertise are HIV/AIDS, Myelitis, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome.

Her clinical research consists of co-authoring 58 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Medical College Of Wisconsin
Specialties
Infectious Disease
Licenses
Specialist in PA
Hospital Affiliations
Upmc Presbyterian Shadyside
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

UNIVERSITY OF PITTSBURGH PHYSICIANS
3601 5th Ave, Pittsburgh, PA 15213
Other Locations
UNIVERSITY OF PITTSBURGH PHYSICIANS
200 Lothrop St, Pittsburgh, PA 15213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase I Study to Evaluate the Safety, Tolerability and Immunogenicity of a Therapeutic HIV Vaccine Composed of Autologous Dendritic Cells Loaded with Autologous Inactivated Whole Virus or Conserved Peptides in ART-treated HIV-infected Adults
A Phase I Study to Evaluate the Safety, Tolerability and Immunogenicity of a Therapeutic HIV Vaccine Composed of Autologous Dendritic Cells Loaded with Autologous Inactivated Whole Virus or Conserved Peptides in ART-treated HIV-infected Adults
Enrollment Status: Completed
Publish Date: February 24, 2025
Intervention Type: Biological
Study Drugs: a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides, a1DC + no antigen, pgDC + inactivated whole autologous HIV, pgDC + conserved HIV peptides, pgDC + no antigena1DC
Study Phase: Phase 1
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Drug
Study Drugs: Doravirine, Tenofovir alafenamide, Emtricitabine, Lamivudine, Integrase strand transfer inhibitors, Tenofovir disproxil fumarate
Study Phase: Phase 4
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2024
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
A Randomized, Double-Blind Phase 1 Safety and Pharmacokinetic Study of Q-Griffithsin Enema Administered Rectally to HIV-1 Seronegative Adults
A Randomized, Double-Blind Phase 1 Safety and Pharmacokinetic Study of Q-Griffithsin Enema Administered Rectally to HIV-1 Seronegative Adults
Enrollment Status: Terminated
Publish Date: July 06, 2023
Intervention Type: Drug, Other
Study Phase: Phase 1
APT-POCT-01: An Open Label, Pharmacokinetic Study of Plasma/Urine/Salivary Drug Concentrations Over Fourteen Days Following Drug Intake Cessation, In HIV-Uninfected Healthy Volunteers Dosing to Steady-state to Further Development of Point of Care Diagnostic Testing
APT-POCT-01: An Open Label, Pharmacokinetic Study of Plasma/Urine/Salivary Drug Concentrations Over Fourteen Days Following Drug Intake Cessation, In HIV-Uninfected Healthy Volunteers Dosing to Steady-state to Further Development of Point of Care Diagnostic Testing
Enrollment Status: Completed
Publish Date: March 03, 2022
Intervention Type: Drug
Study Drugs: Dolutegravir, Emtricitabine/Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, Lamivudine
Study Phase: Early Phase 1
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Enrollment Status: Completed
Publish Date: December 27, 2021
Intervention Type: Drug
Study Phase: Phase 2
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Pilot Study of Dipyridamole as a Modulator of Immune Activation and Systemic Inflammation in HIV-1-Infected Subjects on Antiretroviral Therapy- DAIDS-ES ID 11987
A Phase I/II Pilot Study of Dipyridamole as a Modulator of Immune Activation and Systemic Inflammation in HIV-1-Infected Subjects on Antiretroviral Therapy- DAIDS-ES ID 11987
Enrollment Status: Completed
Publish Date: April 11, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 10 Less Clinical Trials

58 Total Publications

A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod.
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod.
Journal: Infectious diseases and therapy
Published: July 12, 2024
Similar Doctors
Expertise in
10
conditions
Dr. Lee H. Harrison
Infectious Disease
Expertise in
10
conditions
Dr. Lee H. Harrison
Infectious Disease

University Of Pittsburgh Physicians

200 Lothrop St, 
Pittsburgh, PA 
 (0.1 mi)
Languages Spoken:
English
See accepted insurances

Lee Harrison is an Infectious Disease provider in Pittsburgh, Pennsylvania. Dr. Harrison is highly rated in 10 conditions, according to our data. His top areas of expertise are Strep Throat, Methicillin-Resistant Staphylococcus Aureus (MRSA), Sepsis, Bacterial Meningitis, and Gastrostomy.

John W. Mellors
Expertise in
4
conditions
Dr. John W. Mellors
Infectious Disease
Expertise in
4
conditions
Dr. John W. Mellors
Infectious Disease
3601 5th Ave, Suite 700 Falk Medical Building, 
Pittsburgh, PA 
412-648-6401
Languages Spoken:
English
See accepted insurances

John Mellors is an Infectious Disease provider in Pittsburgh, Pennsylvania. Dr. Mellors is highly rated in 4 conditions, according to our data. His top areas of expertise are HIV/AIDS, Sepsis, COVID-19, and Severe Acute Respiratory Syndrome (SARS).

Expertise in
2
conditions
Dr. Jessica S. Merlin
Infectious Disease | Palliative Medicine
Expertise in
2
conditions
Dr. Jessica S. Merlin
Infectious Disease | Palliative Medicine

University Of Pittsburgh Physicians

200 Lothrop St, 
Pittsburgh, PA 
 (0.1 mi)
412-647-3553
Languages Spoken:
English
See accepted insurances

Jessica Merlin is an Infectious Disease specialist and a Palliative Medicine provider in Pittsburgh, Pennsylvania. Dr. Merlin is highly rated in 2 conditions, according to our data. Her top areas of expertise are Chronic Pain, HIV/AIDS, Myelitis, and AIDS Dementia Complex.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile